Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer
European Journal of Cancer · 2026-02 · 235 · 116221
DOI: 10.1016/j.ejca.2026.116221 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-02. Verfasst von Xinghao Ai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of M…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Oncology, Jilin Cancer Hospital, Changchun, China.
- Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
- Department of Internal Thoracic Medicine, Hunan Cancer Hospital, Changsha, China.
Zitieren
APA
Ai, X., Guo, R., Zhang, L., Fang, J., Zhang, Y., Chen, J., Zhao, J., Ye, F., Wang, S., Shi, M., Zhang, X., Zhang, F., Li, J., Wang, L., Guo, X., Xu, L., Duan, X., Hu, Y., & Lu, S. (2026). Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European Journal of Cancer, 235, 116221. https://doi.org/10.1016/j.ejca.2026.116221
Vancouver
Ai X, Guo R, Zhang L, Fang J, Zhang Y, Chen J, et al. Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European Journal of Cancer. 2026;235:116221. doi:10.1016/j.ejca.2026.116221
BibTeX
@article{Ai2026,
author = {Ai, Xinghao and Guo, Renhua and Zhang, Liang and Fang, Jian and Zhang, Yiping and Chen, Jianhua and Zhao, Jun and Ye, Feng and Wang, Shumei and Shi, Meiqi and Zhang, Xinwei and Zhang, Fang and Li, Jiakui and Wang, Li and Guo, Xuejie and Xu, Lingmei and Duan, Xianghui and Hu, Yan and Lu, Shun},
title = {Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {235},
pages = {116221},
doi = {10.1016/j.ejca.2026.116221}
}
EUVIMED